![A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy [Ensayo clínico fase IIIb/IV multicéntrico, aleatorizado, doble ciego, con control activo, de 52 semanas de duración, para evaluar la eficacia y tolerabilidad de saxagliptina comparada con glimepirida en pacientes ancianos con diabetes tipo 2 con un control glucémico inadecuado en tratamiento con metfomina en monoterapia]](https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/Adis_logo.png "A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy [Ensayo clínico fase IIIb/IV multicéntrico, aleatorizado, doble ciego, con control activo, de 52 semanas de duración, para evaluar la eficacia y tolerabilidad de saxagliptina comparada con glimepirida en pacientes ancianos con diabetes tipo 2 con un control glucémico inadecuado en tratamiento con metfomina en monoterapia]"){kind=logo}
Trial Profile
A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy [Ensayo clínico fase IIIb/IV multicéntrico, aleatorizado, doble ciego, con control activo, de 52 semanas de duración, para evaluar la eficacia y tolerabilidad de saxagliptina comparada con glimepirida en pacientes ancianos con diabetes tipo 2 con un control glucémico inadecuado en tratamiento con metfomina en monoterapia]
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Glimepiride (Primary) ; Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GENERATION
- Sponsors AstraZeneca
- 04 Nov 2016 Results of post-hoc analysis assessing beta-cell function (n=720) published in the Clinical Therapeutics.
- 09 Jun 2015 Post hoc analysis n=720 (baseline B-cell function and hypoglycaemia risk) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 27 Jun 2012 Actual end date changed from 12 Apr 2012 to 1 Jun 2012, as reported by ClinicalTrials.gov.